Exscientia PLC
NASDAQ:EXAI

Watchlist Manager
Exscientia PLC Logo
Exscientia PLC
NASDAQ:EXAI
Watchlist
Price: 4.84 USD Market Closed
Market Cap: 633.2m USD
Have any thoughts about
Exscientia PLC?
Write Note

Net Margin
Exscientia PLC

-616.5%
Current
-542%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-616.5%
=
Net Income
-129.6m
/
Revenue
21m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
UK
Exscientia PLC
NASDAQ:EXAI
608.4m USD
-617%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
314.7B USD
9%
US
Amgen Inc
NASDAQ:AMGN
147.4B USD
13%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
-5%
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
34.3B EUR
-14%
Country UK
Market Cap 608.4m USD
Net Margin
-617%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 314.7B USD
Net Margin
9%
Country US
Market Cap 147.4B USD
Net Margin
13%
Country US
Market Cap 119.4B USD
Net Margin
-5%
Country US
Market Cap 113.8B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.4B AUD
Net Margin
18%
Country US
Market Cap 82.6B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 34.3B EUR
Net Margin
-14%
No Stocks Found

Exscientia PLC
Glance View

Market Cap
608.4m USD
Industry
Biotechnology

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.

EXAI Intrinsic Value
4.68 USD
Overvaluation 3%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-616.5%
=
Net Income
-129.6m
/
Revenue
21m
What is the Net Margin of Exscientia PLC?

Based on Exscientia PLC's most recent financial statements, the company has Net Margin of -616.5%.